Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy

被引:15
作者
Mitchell, Aaron P. [1 ,6 ]
Goldstein, Daniel A. [2 ,3 ,4 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel
[3] Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[4] Clalit Hlth Serv, Tel Aviv, Israel
[5] Optimal Canc Care Alliance, Ann Arbor, MI USA
[6] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 485 LexingtonAve, 2nd Floor, New York, NY 10017 USA
关键词
SQUAMOUS-CELL CARCINOMA; LAUNCH; SAFETY; HEAD;
D O I
10.1200/JCO.22.01711
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:170 / +
页数:4
相关论文
共 22 条
[1]   Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy [J].
Agrawal, Shruti ;
Feng, Yan ;
Roy, Amit ;
Kollia, Georgia ;
Lestini, Brian .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
[2]   Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure [J].
Bennette, Caroline S. ;
Richards, Catherine ;
Sullivan, Sean D. ;
Ramsey, Scott D. .
HEALTH AFFAIRS, 2016, 35 (05) :805-812
[3]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[4]   Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study [J].
Cohen, Ezra E. W. ;
Soulieres, Denis ;
Le Tourneau, Christophe ;
Dinis, Jose ;
Licitra, Lisa ;
Ahn, Myung-Ju ;
Soria, Ainara ;
Machiels, Jean-Pascal ;
Mach, Nicolas ;
Mehra, Ranee ;
Burtness, Barbara ;
Zhang, Pingye ;
Cheng, Jonathan ;
Swaby, Ramona F. ;
Harrington, Kevin J. .
LANCET, 2019, 393 (10167) :156-167
[5]   Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].
Ferris, R. L. ;
Blumenschein, G., Jr. ;
Fayette, J. ;
Guigay, J. ;
Colevas, A. D. ;
Licitra, L. ;
Harrington, K. ;
Kasper, S. ;
Vokes, E. E. ;
Even, C. ;
Worden, F. ;
Saba, N. F. ;
Iglesias Docampo, L. C. ;
Haddad, R. ;
Rordorf, T. ;
Kiyota, N. ;
Tahara, M. ;
Monga, M. ;
Lynch, M. ;
Geese, W. J. ;
Kopit, J. ;
Shaw, J. W. ;
Gillison, M. L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867
[6]   RANDOMIZED COMPARISON OF CISPLATIN PLUS FLUOROURACIL AND CARBOPLATIN PLUS FLUOROURACIL VERSUS METHOTREXATE IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].
FORASTIERE, AA ;
METCH, B ;
SCHULLER, DE ;
ENSLEY, JF ;
HUTCHINS, LF ;
TRIOZZI, P ;
KISH, JA ;
MCCLURE, S ;
VONFELDT, E ;
WILLIAMSON, SK ;
VONHOFF, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1245-1251
[7]   Alternative dosing regimens for atezolizumab: right dose, wrong frequency [J].
Goldstein, Daniel A. ;
Ratain, Mark J. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) :1153-1155
[8]   Trajectories of Injectable Cancer Drug Costs After Launch in the United States [J].
Gordon, Noa ;
Stemmer, Salomon M. ;
Greenberg, Dan ;
Goldstein, Daniel A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) :319-+
[9]   A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma [J].
Lepik, Kirill V. ;
Fedorova, Liudmila V. ;
Kondakova, Elena V. ;
Zalyalov, Yuri R. ;
Babenko, Elena V. ;
Lepik, Elena E. ;
Kotselyabina, Polina V. ;
Beynarovich, Anastasia V. ;
Popova, Marina O. ;
Volkov, Nikita P. ;
Stelmakh, Lilia V. ;
Baykov, Vadim V. ;
Moiseev, Ivan S. ;
Mikhailova, Natalia B. ;
Kulagin, Alexander D. ;
Afanasyev, Boris V. .
HEMASPHERE, 2020, 4 (05)
[10]  
Liu A., 2022, WATER AIR SOIL POLL